Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee
- 281 Downloads
Flavocoxid is a novel flavonoid-based “dual inhibitor” of the 5-lipoxygenase (5-LOX) enzyme and the cyclooxygenase (COX) enzymes. This study was designed to compare the effectiveness and safety of flavocoxid to naproxen in subjects with moderate to severe osteoarthritis (OA) of the knee.
In this randomized, multicenter, double-blind study, 220 subjects were assigned to receive either flavocoxid (500 mg twice daily) or naproxen (500 mg twice daily) for 12 weeks. The trial was structured to show noninferiority of flavocoxid to naproxen. Primary outcome measures included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subscales and a timed walk.
More than 90% of the subjects in both groups noted significant reduction in the signs and symptoms of knee OA. There were no statistically significant differences in efficacy between the flavocoxid and naproxen groups when the entire intent-to-treat population was analyzed. The flavocoxid group had significantly fewer upper gastrointestinal (UGI) and renal (edema) adverse events (AEs) as well as a strong trend toward fewer respiratory AEs.
Flavocoxid, a first-in-class flavonoid-based therapeutic that inhibits COX-1 and COX-2 as well as 5-LOX, was as effective as naproxen in managing the signs and symptoms of OA of the knee. Flavocoxid demonstrated better UGI, renal (edema), and respiratory safety profiles than naproxen.
Keywords5-lipoxygenase clinical trial cyclooxygenase flavocoxid, flavonoids naproxen osteoarthritis
Unable to display preview. Download preview PDF.
- 13.Martel-Pelletier J, Mineau F, Fahmi H, et al. Regulation of the expression of 5-lipoxygenaseactivating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. Arthritis Rheum. 2004;50:3925–3933.CrossRefPubMedGoogle Scholar
- 23.Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–1255.CrossRefPubMedGoogle Scholar
- 25.Eisen G. Lack of correspondence of risk factors and clinical GI outcomes for patients on nonsteroidal anti-inflammatory drugs (NSAIDs): analysis from the Celecoxib Long-term Arthritis Safety Study (CLASS). Gasteroenterology. 2001;120:A553.Google Scholar
- 31.Burnett BP, Pillai L, Levy RM, editors. Flavocoxid, a natural novel flavonoid-based anti-inflammatory with a broad mechanism of action provides safe and effective inflammatory management of disease. Presented at: Society for Biomolecular Science; April 11–15, 2010; Phoenix, AZ.Google Scholar
- 33.Morgan SL, Baggott JE, Moreland L, Desomond R, Kendrach A. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Medicinal Foods. 2008;12:1–6.Google Scholar
- 39.Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52:591–511.Google Scholar
- 46.Pretorius JC. Flavonoids: a review of its commercial application potential as anti-infective agents. Curr Med Chem. 2003;2:335–353.Google Scholar